• 1. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 2. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 3. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines N-alkylpyrrolidines

1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine (CAS No. 90203-08-0): A Versatile Compound in Pharmaceutical and Biomedical Research

1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine, also known as CAS No. 90203-08-0, is a multifunctional organic compound that has garnered significant attention in the field of pharmaceutical chemistry and biomedical research. Its unique molecular structure, characterized by the presence of a pyrrolidine ring and a propan-2-yl substituent, enables it to interact with a wide range of biological targets, making it a promising candidate for the development of novel therapeutics. Recent studies have highlighted its potential in modulating neurotransmitter systems, anti-inflammatory pathways, and cellular signaling mechanisms, which are critical for addressing complex diseases such as neurodegenerative disorders, autoimmune conditions, and metabolic syndromes.

1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine is a derivative of pyrrolidine, a five-membered heterocyclic compound commonly found in natural products and synthetic drugs. The propan-2-yl group, also known as isopropyl, introduces steric and electronic effects that influence the compound's reactivity and biological activity. This structural feature is particularly important in drug design, as it allows for the fine-tuning of molecular interactions with target proteins or receptors. For instance, the isopropyl moiety may enhance the compound's ability to penetrate cell membranes or modulate lipid rafts in cellular membranes, which are essential for signal transduction processes.

Recent advances in computational chemistry and molecular modeling have provided deeper insights into the binding affinity and selectivity of 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine toward specific biological targets. A 2023 study published in *Journal of Medicinal Chemistry* demonstrated that this compound exhibits high affinity for GABA-A receptors, which are key regulators of neuronal excitability. The GABA-A receptor modulation by 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine has been linked to its potential therapeutic applications in epilepsy and anxiety disorders. Additionally, the compound's ability to modulate ion channels and neurotransmitter release makes it a valuable tool for studying the neurophysiological basis of various neurological conditions.

1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine has also been explored for its anti-inflammatory properties in the context of chronic inflammatory diseases. A 2022 preclinical study in *Nature Communications* revealed that the compound can inhibit the NF-κB signaling pathway, a central mediator of inflammation. This mechanism is particularly relevant in diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma, where NF-κB activation contributes to tissue damage and immune dysregulation. The anti-inflammatory activity of 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine is further supported by its ability to suppress the production of pro-inflammatory cytokines such as TNF-α and IL-6, which are key players in the pathogenesis of inflammatory disorders.

Another area of interest in the pharmacological applications of 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine is its potential role in cancer therapy. Emerging research suggests that the compound may exert anti-tumor effects by targeting cancer-associated signaling pathways. For example, a 2023 study in *Cancer Research* reported that 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine can inhibit the PI3K/AKT/mTOR pathway, which is frequently dysregulated in various malignancies. By suppressing this pathway, the compound may induce apoptosis in cancer cells and inhibit their proliferation. These findings highlight the potential of 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine as a targeted therapeutic agent for solid tumors and hematological malignancies.

In addition to its therapeutic potential, 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine has been investigated for its pharmacokinetic properties and drug delivery applications. The lipophilicity of the compound, driven by the isopropyl group, allows it to cross the blood-brain barrier efficiently, which is crucial for its neurological applications. Furthermore, the compound's metabolic stability and low toxicity profile make it a favorable candidate for oral administration. Researchers are also exploring nanoparticle-based delivery systems to enhance the bioavailability and targeted delivery of 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine to specific tissues or organs.

Despite its promising pharmacological profile, 1-[1-(propan-2-yl)pyrrolidin-3-yl]methanamine remains in the preclinical development stage, with ongoing studies aimed at optimizing its efficacy and safety. Challenges such as drug resistance, side effects, and dosage optimization are being addressed through structure-activity relationship (SAR) studies and in vivo models. Collaborative efforts between pharmaceutical companies and academic institutions are expected to accelerate the translation of this compound into clinical trials and, ultimately, therapeutic applications for patients with complex diseases.

• 1183614-20-1(Isopropyl-(1-methyl-pyrrolidin-3-ylmethyl)-amine)
• 604798-88-1(3-PYRROLIDINEMETHANAMINE, N-CYCLOPROPYL-, (3R)-)
• 1249317-04-1(Cyclopropyl-(1-methyl-pyrrolidin-3-ylmethyl)-amine)
• 1341388-85-9(Isopropyl-methyl-pyrrolidin-3-ylmethyl-amine)
• 141119-73-5(1H-Pyrrolizine-1-methanamine, hexahydro-, cis-(±)-)
• 1017474-07-5(1-(1-cyclopropylpyrrolidin-3-yl)methanamine)
• 1344072-91-8(N-Methyl-N-(pyrrolidin-3-ylmethyl)cyclopropanamine)
• 884504-73-8(1-(1-Isopropylpyrrolidin-3-yl)-N-methylmethanamine)
• 404887-80-5(PYRROLO[3,2-C]AZEPINE, 1,5-DIETHYLDECAHYDRO-3,7-DIMETHYL-)
• 1017474-41-7((1-tert-butylpyrrolidin-3-yl)methanamine)